# A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease

> **NCT06189495** · PHASE2 · RECRUITING · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Systemic Sclerosis Associated Interstitial Lung Disease
- Rheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD)
- Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)

## Interventions

- **DRUG:** GenSci048
- **DRUG:** GenSci048 placebo

## Key facts

- **NCT ID:** NCT06189495
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-30
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-01-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06189495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06189495, "A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06189495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*